博瑞医药
(688166)
| 流通市值：153.70亿 | | | 总市值：153.70亿 |
| 流通股本：4.36亿 | | | 总股本：4.36亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 678,096,598.23 | 324,934,750.4 | 1,223,640,129.98 | 874,249,705.24 |
| 营业总成本 | 615,978,033.86 | 329,340,975.82 | 1,204,341,010.5 | 859,671,361.36 |
| 其他经营收益 | | | | |
| 营业利润 | 60,811,490.05 | -3,688,657.7 | 14,664,116.06 | 22,773,286.49 |
| 利润总额 | 61,000,945.46 | -3,476,899.67 | 13,908,830.66 | 22,414,798.66 |
| 净利润 | 64,484,440.12 | 9,501,405.04 | 36,954,239.18 | 31,386,524.75 |
| 每股收益 | | | | |
| 其他综合收益 | 3,101,668.36 | -327,248 | 36,676,515.56 | -2,579,713.14 |
| 综合收益总额 | 67,586,108.48 | 9,174,157.04 | 73,630,754.74 | 28,806,811.61 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,202,212,695.96 | 2,306,642,462.43 | 1,788,502,174.9 | 1,466,597,706.53 |
| 非流动资产: | | | | |
| 非流动资产合计 | 4,303,066,237.7 | 4,228,409,414.12 | 4,036,339,503.61 | 3,893,472,334.77 |
| 资产总计 | 6,505,278,933.66 | 6,535,051,876.55 | 5,824,841,678.51 | 5,360,070,041.3 |
| 流动负债: | | | | |
| 流动负债合计 | 978,261,184.18 | 991,267,743.87 | 1,280,306,196.28 | 1,167,050,820.96 |
| 非流动负债: | | | | |
| 非流动负债合计 | 2,096,648,056.89 | 2,642,200,687.26 | 1,698,359,977.14 | 1,661,300,790.68 |
| 负债合计 | 3,074,909,241.07 | 3,633,468,431.13 | 2,978,666,173.42 | 2,828,351,611.64 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,052,325,774.52 | 2,530,324,219.57 | 2,521,166,775.02 | 2,448,042,214.54 |
| 股东权益合计 | 3,430,369,692.59 | 2,901,583,445.42 | 2,846,175,505.09 | 2,531,718,429.66 |
| 负债和股东权益合计 | 6,505,278,933.66 | 6,535,051,876.55 | 5,824,841,678.51 | 5,360,070,041.3 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 596,320,941.87 | 248,014,327.23 | 1,254,084,109.38 | 822,177,913.94 |
| 经营活动现金流出小计 | 581,091,508.28 | 359,279,019.5 | 928,893,297.87 | 723,223,052.13 |
| 经营活动产生的现金流量净额 | 15,229,433.59 | -111,264,692.27 | 325,190,811.51 | 98,954,861.81 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 51,396,554.53 | 15,000,000 | 90,808,375.87 | 46,724,294.42 |
| 投资活动现金流出小计 | 301,836,419.85 | 160,715,625.93 | 713,352,924.1 | 599,293,366.52 |
| 投资活动产生的现金流量净额 | -250,439,865.32 | -145,715,625.93 | -622,544,548.23 | -552,569,072.1 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,427,811,863.92 | 1,208,539,613.92 | 1,539,848,100.82 | 965,002,925.81 |
| 筹资活动现金流出小计 | 827,835,604.58 | 517,447,408.66 | 1,042,195,618.6 | 671,336,996.93 |
| 筹资活动产生的现金流量净额 | 599,976,259.34 | 691,092,205.26 | 497,652,482.22 | 293,665,928.88 |
| 汇率变动对现金及现金等价物的影响 | -7,508,690.51 | -2,267,044.22 | 662,598.02 | 6,062,765.14 |
| 现金及现金等价物净增加额 | 357,257,137.1 | 431,844,842.84 | 200,961,343.52 | -153,885,516.27 |
| 期末现金及现金等价物余额 | 1,312,320,411.57 | 1,357,400,016.88 | 955,063,274.47 | 600,216,414.68 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 357,257,137.1 | - | 200,961,343.52 | - |